- Home
- AZI vs IMAB Comparison
AZI vs IMAB Comparison
Compare AZI & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AZI
- IMAB
- Stock Information
- Founded
- AZI 2010
- IMAB 2014
- Country
- AZI China
- IMAB United States
- Employees
- AZI N/A
- IMAB N/A
- Industry
- AZI
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- AZI
- IMAB Health Care
- Exchange
- AZI Nasdaq
- IMAB Nasdaq
- Market Cap
- AZI 93.4M
- IMAB 83.8M
- IPO Year
- AZI 2024
- IMAB 2020
- Fundamental
- Price
- AZI $0.82
- IMAB $1.07
- Analyst Decision
- AZI
- IMAB Strong Buy
- Analyst Count
- AZI 0
- IMAB 3
- Target Price
- AZI N/A
- IMAB $8.00
- AVG Volume (30 Days)
- AZI 155.3K
- IMAB 682.1K
- Earning Date
- AZI 02-15-2025
- IMAB 03-13-2025
- Dividend Yield
- AZI N/A
- IMAB N/A
- EPS Growth
- AZI N/A
- IMAB N/A
- EPS
- AZI N/A
- IMAB N/A
- Revenue
- AZI $117,732,000.00
- IMAB $3,313,984.00
- Revenue This Year
- AZI N/A
- IMAB N/A
- Revenue Next Year
- AZI N/A
- IMAB N/A
- P/E Ratio
- AZI N/A
- IMAB N/A
- Revenue Growth
- AZI 8.62
- IMAB N/A
- 52 Week Low
- AZI $0.75
- IMAB $0.84
- 52 Week High
- AZI $4.05
- IMAB $2.08
- Technical
- Relative Strength Index (RSI)
- AZI N/A
- IMAB 55.17
- Support Level
- AZI N/A
- IMAB $1.00
- Resistance Level
- AZI N/A
- IMAB $1.20
- Average True Range (ATR)
- AZI 0.00
- IMAB 0.12
- MACD
- AZI 0.00
- IMAB 0.02
- Stochastic Oscillator
- AZI 0.00
- IMAB 40.97
About AZI Autozi Internet Technology (Global) Ltd. Class A Ordinary Shares
Autozi Internet Technology (Global) Ltd is one of China's leading and fast-growing lifecycle automotive service providers. It provides high-quality, affordable, and professional one-stop automotive products and services through online and offline channels nationwide. Leveraging its online supply chain cloud platform, SaaS platforms, and the network of MBS stores, It has established an ecosystem of lifecycle automotive services by connecting automotive manufacturers, auto parts manufacturers, and insurance companies with MBS stores and various automotive owners. Its business segments include new car sales, auto parts and auto accessories sales, and automotive insurance-related services. The majority of revenue is from the new car sales segment, and auto parts & auto accessories sales.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).